Syndax Pharmaceuticals Debt to Equity

The latest debt-to-equity ratio for SNDX is 39.03. That is above the Healthcare sector average of 0.26. Investors often review this figure alongside Syndax Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, SNDX currently prints 39.03 for debt-to-equity ratio, while the sector average sits near 0.26. That is roughly 14669.4% above the sector mean. Large gaps often invite a closer look at Syndax Pharmaceuticals's growth, margins, and balance sheet.

A debt-to-equity ratio of 39.03 for Syndax Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (0.26) and with SNDX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting SNDX's debt-to-equity ratio (39.03), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Syndax Pharmaceuticals's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.